| Patents for A61P 21 - Drugs for disorders of the muscular or neuromuscular system (23,287) |
|---|
| 04/14/2005 | CA2582007A1 Buccal, polar and non-polar spray containing diazepam |
| 04/14/2005 | CA2544574A1 Stable vitamin b6 derivative |
| 04/13/2005 | EP1521824A2 Nucleic acid-associated proteins |
| 04/13/2005 | EP1521763A2 Novel nonsteroidal anti-inflammatory substances, compositions and methods for their use |
| 04/13/2005 | EP1521735A2 Single amino acid based compounds for counteracting effects of reactive oxygen species and free radicals |
| 04/13/2005 | EP1521597A1 LIQUID FORMULATIONS WITH HIGH CONCENTRATION OF HUMAN GROWTH HORMONE (hgh) COMPRISING 1,2-PROLPYLENE GLYCOL |
| 04/13/2005 | EP1521596A1 Liquid formulations with a high concentration of human growth hormone (hgh) comprising glycine |
| 04/13/2005 | EP1521593A2 Transdermal botulinum toxin compositions |
| 04/13/2005 | EP1303296B1 Composition containing an iron complexing protein and a precursor of nitrogen monoxide metabolism and/or a chemical donor of nitrogen monoxide and uses thereof |
| 04/13/2005 | EP1212052B1 Therapeutic uses of polymers and oligomers comprising gamma-hydroxybutyrate |
| 04/13/2005 | EP1090105B1 Non-embryonic ependymal neural stem cells and method for their isolation |
| 04/13/2005 | CN1606694A Methods for monitoring and treating amyotrophic lateral sclerosis |
| 04/13/2005 | CN1606554A Beta-lactamyl vasopressin v1aantagonists |
| 04/13/2005 | CN1196680C Modulators of dopamine neurotransmission |
| 04/12/2005 | US6878726 For therapy and prophylaxis inflammation, other inflammation associated disorders, such as arthritis, neurodegeneration and colon cancer, in mammals, dogs, cats or livestock animals |
| 04/12/2005 | US6878701 Potassium channel blocking agents |
| 04/12/2005 | CA2385854C Formulation for menopausal women |
| 04/07/2005 | WO2005030256A1 INHIBITION OF NERVE CELL DEATH BY INHIBITING DEGRADATION OF SHC3, ATF6 OR CREBL1 BY HtrA2 AND METHOD OF AMELIORATING NEURODEGENERATIVE DISEASES |
| 04/07/2005 | US20050075394 Phenethanolamine derivatives for treatment of respiratory diseases |
| 04/07/2005 | US20050075334 Novel compounds |
| 04/07/2005 | US20050075288 Pharmaceutical and cosmetic compositions comprising plgf-1 |
| 04/07/2005 | US20050075273 condensation aerosols; for treatment of pain or alcohol abuse; kits |
| 04/07/2005 | US20050074764 Using presence of point mutations in nicotinic acetylcholine receptor (nACHR) gene as diagnostic/prognosic tool in detction and treatment of indicator of cardiovascular, nervous system, vision and pain disorders |
| 04/07/2005 | US20050074751 Binding viral protein during latency life cycle; binding of antibodies to excellular segments of protein; immobilization; removal of infecting cells; autoimmune disease, lupus, antiarthritic agents |
| 04/07/2005 | US20050074470 Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage |
| 04/07/2005 | US20050074461 Transdermal botulinum toxin compositions |
| 04/07/2005 | US20050074436 Systems and methods for treating patients with processed lipoaspirate cells |
| 04/07/2005 | CA2539976A1 Therapeutic beta aminoacids |
| 04/06/2005 | EP1520043A2 METHODS FOR THE IDENTIFICATION OF IKKa FUNCTION AND OTHER GEN ES USEFUL FOR TREATMENT OF INFLAMMATORY DISEASES |
| 04/06/2005 | EP1519957A2 Use of hmgb1 in the treatment of tissue damage and/or to promote tissue repair |
| 04/06/2005 | EP1519733A1 Compositions for cancer therapy comprising saponins or sapogenins |
| 04/06/2005 | EP1519726A1 Utilization of heteroarene carboxamide as dopamine-d3 ligands for the treatment of cns diseases |
| 04/06/2005 | EP1519720A2 Novel formate salt of o-desmethyl-venlafaxine |
| 04/06/2005 | EP1406898B1 Substituted piperazine compounds and their use as fatty acid oxidation inhibitors |
| 04/06/2005 | CN1604901A Bicyclic oxopyridine and oxopyrimidine derivatives |
| 04/06/2005 | CN1604900A 6-aminomorphinane derivatives, method for production and use thereof |
| 04/06/2005 | CN1195745C Antiviral macrocyclic compounds |
| 04/06/2005 | CN1195522C Benzodiazepine derivatives |
| 04/06/2005 | CN1195513C Tocopherols, tocotrienols, other chroman and side chain derivatives and uses |
| 04/05/2005 | US6875789 Pyrazole-derived kinase inhibitors and uses thereof |
| 04/05/2005 | US6875779 Cyclooxygenase inhibitor |
| 04/05/2005 | US6875570 Proteins and nucleic acids encoding same |
| 03/31/2005 | WO2005028455A1 Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient |
| 03/31/2005 | WO2005027921A1 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a bisphosphonate |
| 03/31/2005 | WO2005027918A1 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a cyclooxgenase-2 inhibitor |
| 03/31/2005 | WO2005027916A1 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and aromatase inhibitors |
| 03/31/2005 | WO2005027915A1 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone |
| 03/31/2005 | WO2005027914A1 2-alkylidene-19-nor-vitamin d derivatives for the treatment of frailty, muscle damage or sarcopenia |
| 03/31/2005 | WO2005027913A1 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue |
| 03/31/2005 | WO2003018756A3 Methods for preparing purified prostaglandin e synthase |
| 03/31/2005 | US20050070689 Nucleotide sequences coding transmembrane activator and CAML interactor (TACI) protein for use in treatment and prevention of autoimmune disorders |
| 03/31/2005 | US20050070590 possessing anti-cancer activity, anti-inflammatory activity, anti-obesity activity, and/or hair growth promotion activity |
| 03/31/2005 | US20050070559 Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3 |
| 03/31/2005 | US20050070558 For example, [4-(2,4-Dioxo-1,3-dipropyl-2,3,4,5-tetrahydro-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetic acid; useful in preventing mast cell degranulation and therefore useful in treatment of diseases induced by activation of A2b receptor and mast cell activation such as asthma, allergic reactions |
| 03/31/2005 | US20050070459 treating Type I diabetes, septic shock, multiple sclerosis, inflammatory bowel disease (IBD) and Crohn's disease with BoroProline-Pinacol or other proline derivatives; dipeptidylpeptidase inhibitor |
| 03/31/2005 | US20050069922 Using presence of short expansion sequences in poly(A) binding protein II (PAB II) gene as diagnostic indicator of disease associated with polyalanine and protein accumulation in nucleus |
| 03/31/2005 | US20050069878 Proteins associated with cell growth, differentiation, and death |
| 03/31/2005 | US20050069876 Polypeptide for use in diagnosis, treatment and prevention of cell proliferative, autoimmune, inflammatory, cardiovascular, neurological and developmental disorders. |
| 03/31/2005 | US20050069537 Stimulants of survival of cells; binding of cellular adhesion molecular; prevent apoptosis |
| 03/31/2005 | US20050069492 As neuroprotective agents in the therapy of neuronal disorders of the central and peripheral nervous systems |
| 03/31/2005 | CA2539359A1 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a bisphosphonate |
| 03/31/2005 | CA2539357A1 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone |
| 03/31/2005 | CA2538993A1 2-alkylidene-19-nor-vitamin d derivatives for the treatment of frailty, muscle damage or sarcopenia |
| 03/30/2005 | EP1242089B1 Use of adatanserin for the treatment of acute neurodegenerative disorders |
| 03/30/2005 | EP1224163B1 Use of carbonylamino derivatives against cns disorders |
| 03/30/2005 | EP1091942B1 Potassium channel blocking agents |
| 03/30/2005 | CN1602311A Use of 2-amino-4-pyridylmethyl-thiazoline derivatives as inhibitors of inducible NO-synthase |
| 03/30/2005 | CN1602310A Benzothiazoles compound |
| 03/30/2005 | CN1602292A Unsaturated 1-amino-alkylcyclohexane NMDA, 5HT3 and neuronal nicotinic receptor antagonists |
| 03/30/2005 | CN1602191A Compounds and uses thereof for decreasing activity of hormone-sensitive lipase |
| 03/30/2005 | CN1602187A Valdecoxib-based composition prepared by spray drying process and exhibiting rapid oral dissolution |
| 03/29/2005 | US6872751 Composition and method for augmenting or restoring the production of fetal protein in patient in need thereof |
| 03/29/2005 | US6872738 Product comprising at least a no synthase inhibiting substance associated with at least a phospholipase a2 inhibiting substance |
| 03/29/2005 | US6872733 Benzimidazolone compounds |
| 03/29/2005 | US6872731 Imidazo-pyridine derivatives as ligands for GABA receptors |
| 03/29/2005 | US6872714 Methods to modulate conditions mediated by the CXCR4 receptor |
| 03/29/2005 | US6872397 Administering to the patient a therapeutical amount of botulinum toxin of a selected serotype until patient experiences loss of clinical response to the toxin and then administering another botulinum toxin of a different serotype |
| 03/24/2005 | WO2005026337A2 Adenoviral vector for infecting cells deficient in a car receptor |
| 03/24/2005 | WO2004096269A3 Botulinum neurotoxin for treating tics and obsessive compulsive behaviors |
| 03/24/2005 | WO2003104407A3 T cell receptor cdr3 sequences and methods for detection |
| 03/24/2005 | WO2002092759A9 Molecules for disease detection and treatment |
| 03/24/2005 | US20050065354 Administering prodrugs of metabolites such as 5-methyl-7-ethyl carbonate -isoflavone to increase concentration of flavonoids |
| 03/24/2005 | US20050065195 Oxadiazolyl-biphenylcarboxamides and their use as p38 kinase inhibitors |
| 03/24/2005 | US20050065193 Carbamates of 2-heterocyclic-1,2-ethanediols |
| 03/24/2005 | US20050065180 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and a growth hormone secretagogue |
| 03/24/2005 | US20050065173 Gene for spinal muscular atrophy |
| 03/24/2005 | US20050065130 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and a cyclooxgenase-2 inhibitor |
| 03/24/2005 | US20050065129 Muscular disorders |
| 03/24/2005 | US20050065126 Synergistic mixture; osteoporosis therapy; bone disorders; anticancer agents; obesity |
| 03/24/2005 | US20050065117 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and a bisphosphonate |
| 03/24/2005 | US20050065088 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and parathyroid hormone |
| 03/24/2005 | US20050064586 Somatic cell derived embryonic stem cells and its differentiated cells |
| 03/24/2005 | US20050064491 Transport protein for use as tool in identifying modulator for treatment of sleep, nervous suystem, anixety, eating, cardiovascular and pain disordere |
| 03/24/2005 | US20050064014 Use of cystathionine |
| 03/23/2005 | EP1516064A2 Methods of using 46828, a human acyl-coa synthetase |
| 03/23/2005 | EP1515959A1 Pharmaceutical salts of reboxetine |
| 03/23/2005 | EP1515742A2 Genes involved in regulating angiogenesis, pharmaceutical preparations containing same and applications thereof |
| 03/23/2005 | EP1515731A1 Anti-spasmodic comprising xenon |
| 03/23/2005 | EP1515727A2 (halo-benzo carbonyl)heterobicyclic p38 kinase inhibiting agents |
| 03/23/2005 | EP1515716A2 Indole derivatives having anti-angiogenetic activity |